摘要
目的探讨尼妥珠单抗在头颈部鳞状细胞癌患者术前新辅助治疗中的应用效果和安全性。方法采用随机抽签法将30例头颈部鳞状细胞癌患者分为A组和B组,每组15例,两组患者术前均进行新辅助治疗,A患者予以顺铂+氟尿嘧啶(PF)方案化疗,B组患者予以PF方案化疗+尼妥珠单抗治疗。比较两组患者的临床疗效、不良反应发生情况、后续治疗情况及生活质量。结果B组患者的总有效率高于A组,差异有统计学意义(P﹤0.05);两组患者的疾病控制率比较,差异无统计学意义(P﹥0.05)。两组患者1~2级和3~4级不良反应发生率比较,差异均无统计学意义(P﹥0.05)。B组患者保留器官功能根治术实施率明显高于A组,差异有统计学意义(P﹤0.01)。治疗后,两组患者的生活质量评分均高于本组治疗前,B组患者的生活质量评分高于A组,差异均有统计学意义(P﹤0.05)。结论尼妥珠单抗应用于头颈部鳞状细胞癌患者的术前新辅助治疗中疗效显著,安全性较高,可提高器官功能保留手术的实施率和生活质量,值得推广应用。
Objective To investigate the effect and safety of nimotuzumab in preoperative neoadjuvant therapy for patients with head and neck squamous cell carcinoma.Method A total of 30 patients with head and neck squamous cell carcinoma were randomly divided into group A and group B,with 15 cases in each group.Both groups received neoadjuvant therapy before the surgery.Patients in group A received cisplatin+fluorouracil(PF)regimen chemotherapy,and patients in group B received PF regimen chemotherapy plus nimotuzumab.The clinical curative effect,incidence of adverse events,follow-up treatment,and the quality of life of the two groups were compared.Result The total response rate of group B was higher than that of group A,and the difference was statistically significant(P<0.05).There was no significant difference in the disease control rate between the two groups(P>0.05).There were no significant differences in the incidence of adverse events of 1-2 degrees and 3-4 degrees between the two groups(P>0.05).The implementation rate of organ function-preserving radical surgery in group B was significantly higher than that in group A,and the difference was statistically significant(P<0.01).After the treatment,the quality of life scores in the two groups were higher than those before the treatment,and the score in group B was higher than that in group A,and the differences were statistically significant(P<0.05).Conclusion The application of nimotuzumab in preoperative neoadjuvant therapy for patients with head and neck squamous cell carcinoma has a remarkable curative effect with reliable safety.It would improve the implementation rate of organ function-preserving surgery and patients’quality of life and is worthy of popularization and application.
作者
吕根梅
罗克勍
田克强
曾汶
肖富福
聂晓明
LYU Genmei;LUO Keqing;TIAN Keqiang;ZENG Wen;XIAO Fufu;NIE Xiaoming(Department of Medicine and Mechanics,Ganzhou Cancer Hospital,Ganzhou 341000,Jiangxi,China;Department of Head and Neck,Ganzhou Cancer Hospital,Ganzhou 341000,Jiangxi,China)
出处
《癌症进展》
2023年第5期535-538,共4页
Oncology Progress
基金
赣州市卫生健康委员会市级科研计划项目(2020-2-52)。
关键词
尼妥珠单抗
头颈部鳞状细胞癌
新辅助治疗
临床疗效
nimotuzumab
head and neck squamous cell carcinoma
neoadjuvant therapy
clinical efficacy
